




CRO SERVICES - PRE-CLINICAL FIBROSIS DRUG VALIDATION



Market need and potential

Fibrosis of the heart, liver, lungs and kidneys contribute to approximately 40 percent of deaths in the industrial world. Despite the enormous impact on human health worldwide there are currently no effective agents that can prevent, arrest, or reverse fibrosis. Current treatments aim at treating the complications of disease, rather than the cause.

The need for new anti-fibrotic agents that can reverse fibrotic disease and thereby increase survival rates is great. However, a major challenge is the translation of basic molecular mechanisms into the clinical setting. This gap is partly due to the current lack of good and reliable pre-clinical models for substance efficacy testing.

Drug developers in the fibrosis field strongly request new experimental models that better reflect human fibrotic disease conditions. More than 200 drug developers and other stakeholders have so far been identified as potential clients. The market for liver fibrosis alone is estimated to exceed 2.8 billion USD in 2017, and the global therapeutic market for NASH, a type of Nonalcoholic Fatty Liver Disease, is estimated to reach 1.6 billion USD in 2020.

Business Idea and Services

InfiCure Bio has developed game-changing tools for pharma developers to more effectively validate new drugs against liver fibrosis. InfiCure Bio are the first on the market to offer specific efficacy tests for anti-fibrotic drugs in an all-new unique mouse model - the N-IF mouse.

The company can boast a highly qualified team of experts that with unique expertise in the science of fibrosis development, experimental animals, immunology and autoimmunity.

Currently, InfiCure Bio is offering drug developers a full-service option where candidate drugs are delivered to the laboratory facilities in Umeå to be tested for efficacy at the company labs. However, a licencing option service is being developed for clients who prefer to manage and control the entire drug validation process in-house at their own laboratories.

Vision

InfiCure Bio aims at becoming the world leader in preclinical testing of anti-fibrotic drugs by establishing the N-IF mouse as a first choice for efficacy testing of anti-fibrotic drug candidates.

Competition

All current alternatives to the N-IF mouse requires treatment with chemicals or by surgery to induce fibrosis development. This is more time consuming and hampers reproducibility, a key aspect of high quality laboratory studies.

Competitive advantages

InfiCure Bio has developed a unique pre-clinical mouse model that has several crucial benefits:

- 100 percent reproducible model - high level of consistency between specimens.
- The model displays spontaneous development of fibrosis in multiple organs.
- Early onset provides shortened test protocols.
- The development of fibrosis is preceded by a state of chronic inflammation - as observed in several human conditions.

The advantages with the N-IF mouse allows InfiCure Bio to offer cost-effective pre-clinical studies in tailored and customized output formats for efficacy tests of fibrotic compounds.

This whole-organism model, in combination with InfiCure Bio's expertise, is a new service previously unavailable for the biomedical industry.

Reasons to invest

InfiCure Bio is the only company on the market with access to the N-IF mouse model for testing of anti-fibrotic agents.

This new unique model has the potential to become the golden standard for efficacy testing of new anti-fibrotic drugs.

Fibrosis is a global health problem and the total potential market in Europe and North America is estimated at more than 900 million SEK.

Pipeline products are new and unique models for NASH, renal fibrosis and lung fibrosis.

The revenue of the company is expected to increase from just over 1 M SEK during 2017 to more than 78 M SEK by 2021.

COMPANY PROFILE

Contact

Sofia Mayans, CEO
sofia.mayans@infiCurebio.com
+46 70 366 46 66

Website

www.infiCurebio.com

Therapeutic area

Pre-clinical drug validation

Development stage

International sales ongoing, US customer (dec 2016). Licence option development.

Founded

2015

IPR

Patent application pending for US market.

Capital need

16 M SEK through 2020.

Capital will cover further validation of the N-IF model, validation of pipeline projects, marketing and sales and patent development.

Management / Board of directors

Sofia Mayans - CEO, Board member
Åsa Larefalk - CPO, Board member
Dan Holmberg - CSO, Chairman

Advisory board

Lars Stenlund
Mats Strömquist
Gunnar Skogman

Investors & partners

Vinnova
Tillväxtverket,
Familjen Ehring-Perssons stiftelse